Postmenopausal hormone replacement therapy and cardiovascular system;Postmenopozal hormon replasman (yerine koyma) tedavisi ve kardiyovasküler sistem

Turk Kardiyoloji Dernegi Arsivi

Volumn 38, Issue SUPPL. 1, 2010, Pages 32-40

  Yildirir, Aylin ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Cardiovascular risk; Hormone replacement therapy; Menopause

Indexed keywords

ESTROGEN;

ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; DISEASE COURSE; HORMONE SUBSTITUTION; HUMAN; LIFESTYLE MODIFICATION; POSTMENOPAUSE; REVIEW;

AGE FACTORS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; POSTMENOPAUSE; WOMEN'S HEALTH;

EID: 77952305193     PISSN: 10165169     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI trial. JAMA 1995;273:199-208.
2. Sack MN, Rader DJ, Cannon RO, 3rd. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 1994;343:269-270.
3. Wagner JD, Clarkson TB, St Clair RW, Schwenke DC, Shively CA, Adams MR. Estrogen and progesterone replacement therapy reduces low density lipoprotein accumulation in the coronary arteries of surgically postmenopausal cynomolgus monkeys. J Clin Invest 19991;88:1995-2002.
4. Varas-Lorenzo C, Garcia-Rodriguez LA, Perez-Gutthann S, Duque-Oliart A. Hormone replacement therapy and incidence of acute myocardial infarction. A population-based nested case-control study. Circulation 2000;101:2572-2578.
5. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-941. (Pubitemid 32003509)
6. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613. (Pubitemid 28502636)
7. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-529. (Pubitemid 30650747)
8. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;360:2001-2008. (Pubitemid 34761611)
9. Cherry N, Gilmour K, Hannaford P, Heagerty A, Khan MA, Kitchener H, et al. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomized placebo controlled trial. Lancet 2002;360:2001-2008. (Pubitemid 36026578)
10. Clarke SC, Kelleher J, Lloyd-Jones H, Slack M, Schofiel PM. A study of hormone replacement therapy in postmenopausal women with ischemic heart disease: the Papworth HRT atherosclerosis study. BJOG. 2002;109:1056-1062. (Pubitemid 35279139)
11. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534. (Pubitemid 36951364)
12. Lip GY, Blann AD, Jones AF, Beevers DG. Effects of hormone replacement therapy on hemostatic factors, lipit factors, and endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis. Am Heart J 1997;134:764-771.
13. Shaw LJ, Bairey Merz CN, Pepine CJ, Reis SE, Bittner V, Kelsey SF, et al. Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol 2006;47 (3 Suppl):S4-S20. (Pubitemid 43170826)
14. Hu FB, Grodstein F, Hennekens CH, Colditz GA, Johnson M, et al. Age at natural menopause and risk of cardiovascular disease. Arch Intern Med 1999;159:1061-1066. (Pubitemid 29230857)
15. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Chanbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-265. (Pubitemid 34084631)
16. Bush DE, Jones CE, Bass KM, Alters GK, Bruza JM, Ouyang P. Estrogen replacement reverses endothelial dysfunction in postmenopausal women. Am J Med 1998;104:552-558. (Pubitemid 28328768)
17. Sorensen KE, Dorup I, Hermann AP, Mosekilde L. Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function. Circulation 1998;97:1234-1238. (Pubitemid 28169174)
18. Ohmichi M, Kanda Y, Hisamoto K, Morishige K, Takahashi K, Sawada K, et al. Rapid changes of flow-mediated dilatation after surgical menopause. Maturitas. 2003;44:125-131. (Pubitemid 36173970)
19. Williams MR, Westerman RA, Kingwell BA, Paige J, Blombery PA, Sudhir K, et al. Variations in endothelial function and arterial compliance during the menstrual cycle. J Clin Endocrinol Metab 2001;86:5389-5395. (Pubitemid 33070265)
20. Kalantaridou SN, Naka KK, Papanikolaou E, Kazakos N, Kravariti M, Calis KA, et al. Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy. J Clin Endocrinol Metab 2004;89:3907-3913. (Pubitemid 39071493)
21. Teede HJ, Liang YL, Kotsopoulos D, Zoungas S, Cravent R, McGrath BP. A placebo-controlled trial of long-term oral combined continuous hormone replacement therapy in postmenopausal women: effects on arterial compliance and endothelial function. Clin Endocrinol 2001;55:673-682. (Pubitemid 34204451)
22. Herrington DM, Espeland MA, Crouse JR 3rd, Robertson J, Riley WA, McBurnie MA, et al. Estrogen replacement and brachial artery flow-mediated vasodilation in older women. Arterioscler Thromb Vasc Biol 2001;21:1955-1961. (Pubitemid 34219747)
23. Vitale C, Mercuro G, Cerquetani E, Marazzi G, Patrizi R, Pelliccia F, et al. Time since menopause influences the acute and chronic effect of estrogens on endothelial function. Arterioscler Thromb Vasc Biol 2008;28:348-352. (Pubitemid 351161210)
24. Humphrey LL, Chan BK, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 2002;137:273-284.
25. American College of Physicians. Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med 1992;117:1016-1037.
26. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613. (Pubitemid 28502636)
27. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
28. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
29. Manson JE, Allison MA, Rossouw JE, Carr JJ, Langer RD, Hsia J, et al. Estrogen therapy and coronary artery calcification. N Engl J Med 2007;356:2591-2602. (Pubitemid 46961004)
30. Alexandersen P, Tanko LB, Bagger YZ, Qin G, Christiansen C. The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women. Climacteric 2006;9:108-118.
31. Salpeter SR, Walsh JME, Greyber E, Salpeter EE. Coronary heart disease events associated with hormone therapy in younger and older women. J Gen Intern Med 2006;21:363-366.
32. Lobo RA. Evaluation of cardiovascular event rates with hormone therapy in healthy, early postmenopausal women: results from 2 large clinical trials. Arch Intern Med 2004;164:482-484.
33. van der Schouw YT, Grobbee DE. Menopausal complaints, oestrogens, and heart disease risk: an explanation for discrepant findings on the benefits of post-manopausal hormone therapy. Eur Heart J 2005;26:1356-1361.
34. Gast GC, Grobbee DE, Pop VJ, Keyzer JJ, Wijnandsvan Gent CJ, Samsioe GN, et al. Menopausal complaints are associated with cardiovascular risk factors. Hypertension 2008;51:1-7.
35. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939-953.
36. Le Gal G, Gourlet V, Hogrel P, Plu-Bureau G, Touboul PJ, Scarabin PY. Hormone replacement therapy use is associated with a lower occurrence of carotid atherosclerotic plaques but not with intima-media thickness progression among postmenopausal women. The vascular aging (EVA) study. Atherosclerosis 2003;166:163-170. (Pubitemid 35449612)
37. Angerer P, Stork S, Kothny W, Schmitt P, von Schacky C. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial. Arterioscler Thromb Vasc Biol 2001;21:262-268. (Pubitemid 32125376)
38. Hodis HN, Mack WJ, Azen SP, Lopo RA, Shoupe D, Mahrer PR, et al. Hormone therapy and the progression of coronary artery atherosclerosis in postmenopausal women. N Engl J Med 2003;349:535-545. (Pubitemid 36951365)
39. Stork S, van der Schouw YT, Grobbee DE, Bots ML. Estrogen, inflammation and cardiovascular risk in women: a critical appraisal. Trends Endocrinol Metab 2004;15:66-72. (Pubitemid 38253008)
40. Rossouw JE. Coronary heart disease in menopausal women: implications of primary and secondary prevention trials of hormones. Maturitas 2005;51:51-63.
41. Adams MR, Register TC, Golden DL, Wagner JD, Williams JK. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:217-221.
42. Gerhard M, Walsh BW, Tawakol A, Haley EA, Creager SJ, Seely EW, et al. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation 1998;98:1158-1163. (Pubitemid 28436164)
43. Waters DD, Alderman EL, Hsia J, Howard BV, Cobb FR, Rogers WJ, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA 2002;288:2432-2440. (Pubitemid 35340539)